
“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is for people whose breast cancer has grown into surrounding tissue or it has spread elsewhere in the body.
Triple negative breast cancer are cancers without receptors for:
Chemotherapy is one of the usual treatments for triple negative breast cancer that has spread. You might have a chemotherapy drug called paclitaxel. Doctors are always looking for way to improve treatment. In this trial, they are looking at adding a drug called atezolizumab to chemotherapy.
Atezolizumab is a type of immunotherapy. It blocks a protein called PD-1. This triggers the to attack and kill cancer cells.
Doctors hope that adding atezolizumab to paclitaxel can improve the way it works.
In this trial, some people have paclitaxel and atezolizumab. And some have paclitaxel and a dummy drug ().
The main aims of this trial are to:
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply.
You:
Who can’t take part
You cannot join this trial if any of these apply.
Cancer related
You:
Medical conditions
You:
Other
You:
This phase 3 trial is taking place worldwide. The researchers hope 495 people will take part including 20 in the UK.
It is a randomised trial. You are put into treatment groups by a computer. Neither you nor your doctor can decide which group you are in. And neither of you will know which group you are in. This is called a double blind trial.
You have 1 of the following:
You are 2 times more likely to have atezolizumab.
You have treatment in cycles. Each treatment period is 4 weeks. You have all your treatment as a drip into a vein.
The first day of each treatment cycle is called day 1. You have atezolizumab or the dummy drug on:
This takes about an hour each time.
You have paclitaxel on:
This takes about an hour each time.
You have treatment for as long as it is working and the side effects aren’t too bad
Quality of life
The trial team will ask you to fill out a questionnaire before you start treatment and at set times during treatment. The questionnaire will ask about side effects and how you’ve been feeling. This is called a .
Samples for research
You give some extra blood samples during treatment. You give the samples at specific times and the trial team will give you more information about this. They plan to use the samples to:
The doctors will ask permission to collect 2 extra tissue samples. You do not have to agree to give these samples if you don’t want to. You can still take part in the trial.
You see a doctor and have some tests before you can take part. These include:
During treatment, each hospital visit takes about 3 to 5 hours. You shouldn’t need to stay overnight.
At each visit you see a doctor for a check up and blood tests.
You have a CT scan or MRI scan:
When you finish treatment, you see the trial team after 1 month.
Follow up
When you finish treatment the trial team will contact you every 3 months to see how you are getting on. They might phone you or see you at routine hospital appointments. Or they might check your medical notes.
The trial team monitor you during the time you have treatment and you’ll have a phone number to call them if you are worried about anything.
The most common side effects of atezolizumab include:
The most common side effects of paclitaxel include:
The trial doctor will explain all the possible side effects before you join the trial.
We have more information about:
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor David Miles
Roche
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”